Lead Sponsor

Lineage Cell Therapeutics, Inc.

Age

18 - 69 years

Sex

ALL

Healthy Volunteers

No

•Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
•Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
•Last fully preserved single neurological level (SNL) from C-4 to C-7
•From 18 through 69 years of age at time of injury
•Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring
•Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury
•Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI

•SCI due to penetrating trauma
•Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI
•Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations
•Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised
•Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression
•History of any malignancy (except non-melanoma skin cancers)
•Pregnant or nursing women
•Body mass index (BMI) \> 35 or weight \> 300 lbs.
•Active participation in another experimental procedure/intervention

Related studies

NCT04894734 · Spinal Cord Injury at T1-T12 Level, Traumatic Thoracic Spinal Cord Contusion, and more

NCT07357428 · Amyotrophic Lateral Sclerosis, Neuromuscular Disease, and more

NCT04937868 · Abdominal Injury, Pelvic Fracture, and more

NCT07299734 · Cervical Spinal Cord Injury

NCT07127172 · Tetraplegia/Tetraparesis, Quadriplegia, and more

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury